ANAPTYSBIO, INC. (ANAB) — Fundamental Analysis

AnaptysBio (ANAB) has undergone a dramatic financial turnaround in fiscal year 2025, crossing into operating profitability for the first time in its history based on the data available here. Revenue surged to $234.6 million — more than 2.5x its 2024 level — driven primarily by a major licensing or collaboration milestone, while the operating margin swung decisively into positive territory at roughly 20%. The company carries no debt, maintains a very strong current ratio, and spends almost nothing on capital expenditures, reflecting its asset-light, R&D-focused biotech model. The path here was not smooth — losses were deep and persistent from 2017 through 2024 — but 2025 marks a meaningful inflection point. Investors should understand that revenue at a clinical-stage biotech like ANAB is highly lumpy and milestone-driven, so sustaining this trajectory depends heavily on continued commercial or partnering success for its pipeline assets.

Snapshot & Big Picture

AnaptysBio is a clinical-stage biotechnology company focused on inflammatory diseases. Its revenue has historically consisted of collaboration and licensing payments — which are inherently lumpy — rather than steady product sales. From 2017 through 2023, the company was burning cash at a significant rate as it advanced its pipeline. A step-change in revenue occurred in 2025, with $234.6 million reported, most likely reflecting a large collaboration or licensing event. Critically, gross margin data was not available in the filings for any year, so profitability analysis relies on operating and net margin figures. The company has consistently carried zero long-term debt across all years in the dataset, a notable sign of financial discipline or equity-funded operations typical of biotech.

Latest Quarter Snapshot

No quarterly data from a 10-Q filing was available for inclusion in this analysis. The most recent 10-Q on file (for the period ending March 31, 2026, filed May 12, 2026) was listed as a source but its parsed financial data was not provided. For the most current intra-year picture — including any Q1 2026 revenue, cash position, or operating expense updates — readers should refer directly to that filing linked in the Source Filings section below. The annual 2025 figures remain the most complete view of AnaptysBio's financial position available here.

Profitability

AnaptysBio's profitability history is a story of deep, persistent losses giving way — at least in 2025 — to a meaningful positive inflection. From 2017 through 2024, every single fiscal year posted negative EBITDA and negative operating and net margins, with the worst years (2018, 2019, 2022, 2023) seeing operating losses that were more than 10x reported revenue. This reflects the reality of a pre-commercial biotech funding R&D without a marketed product generating recurring revenue.

The two partial exceptions were 2020 (operating margin -31.8%) and 2021 (operating margin -89.9%), when a collaboration agreement brought in $75M and $63M respectively — but even then, underlying operating expenses exceeded revenues. In 2025, however, EBITDA turned positive at $48.5 million and the operating margin reached +20.4%, a historic first for the company in this dataset. Net margin remained slightly negative at -5.6%, suggesting that below-the-operating-line items (such as taxes or non-cash charges) still created a small net loss, but the direction of travel is unambiguously improved. Sustaining this will require either continued milestone or royalty receipts, or progression to commercial revenues.

Financial Health

AnaptysBio's balance sheet has consistently been a strength. The company has carried no long-term debt in any year represented in this dataset — the debt-to-equity ratio is null across all periods, indicating zero reported debt. Current ratios have been consistently elevated, ranging from a low of 9.07x (2025) to a high of 34.40x (2021), reflecting large cash and liquid asset balances relative to near-term liabilities. Even at the 2025 "low" of 9.07x, the company has more than nine dollars of current assets for every dollar of current liabilities — an extremely comfortable liquidity position.

Capital expenditures have been trivially small throughout the company's history, consistent with an asset-light biotech that outsources manufacturing and lab operations:

The CapEx-to-revenue ratio in early years (2018: 21.3%, 2019: 10.1%) looks high but is an artifact of the denominator being very small (low revenues), not because the company was spending heavily on physical assets. In absolute dollar terms, capital expenditures have never exceeded $1.4 million in any single year and have fallen to just $87K in 2025. This confirms that AnaptysBio has minimal reinvestment needs in fixed assets — its primary capital deployment is into R&D expenses, which flow through the income statement rather than the balance sheet. Capital intensity is trending decisively downward, which is a positive indicator for free cash flow conversion as revenues grow.

Growth

Revenue growth at AnaptysBio is extremely difficult to interpret using traditional CAGR measures because the company's revenues are milestone- and collaboration-driven, creating enormous year-to-year volatility rather than organic compounding growth.

The 10-year CAGR is not available because the SEC filing history in this dataset does not extend back a full decade from 2025 (the earliest year available is 2017, giving only an 8-year window). The 3-year CAGR of 183.6% is eye-catching but almost entirely reflects the base effect of 2022 being a particularly low-revenue year ($10.3M) rather than genuine compounding growth. The 5-year CAGR of 25.6% — anchored to the $75M collaboration year of 2020 — is a more grounded measure and still represents solid growth, though again the milestone-driven nature of this revenue means neither figure should be extrapolated linearly into the future.

Source Filings

• 10-Q filed 2026-05-12 (Period ending March 31, 2026)
• 10-K filed 2026-03-03 (Fiscal Year ending December 31, 2025)